Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Celularity Inc

Accession: 0001493152-26-049203

Filed: 2026-10-29

Period: 2026-10-29

CIK: 0001752828

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001752828

0001752828

2026-10-29

2026-10-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 29, 2026

Celularity

Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38914

83-1702591

(State

or other jurisdiction

of

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

170

Park Ave

Florham

Park, New Jersey

07932

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (908) 768-2170

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instructions A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Class

A Common Stock, $0.0001 par value per share

CELU

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01. Other Events.

On

October 29, 2026, Celularity Inc. (“Celularity”) issued a press release announcing an exclusive manufacturing and commercial

collaboration with Vesalius Longevity Labs Inc. (“Vesalius”), for U.S.-based purification, processing, analytical testing

and manufacture of peptide active pharmaceutical ingredients under Vesalius’s Peptual® brand.

The

collaboration pairs Celularity’s manufacturing infrastructure and technical expertise with Vesalius’s Peptual platform to

advance U.S.-based production of peptide APIs in accordance with current good manufacturing practice standards at Celularity’s

New Jersey facility. The parties intend to establish a domestic supply platform that supports consistent product quality and lot-level

traceability while strengthening the resilience and accountability of the peptide API supply chain.

A

copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

99.1

Press release issued by Celularity Inc. on October 29, 2026.

104

Cover

Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CELULARITY

INC.

Dated:

October 29, 2026

By:

/s/

K. Harold Fletcher

Name:

K.

Harold Fletcher

Title:

Chief

Legal and Strategy Officer

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Celularity

and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

Celularity

to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s

expansion into pharmaceutical ingredient supply

Collaboration

advances Celularity’s regenerative longevity vision and creates an opportunity to expand revenue through its U.S. manufacturing

infrastructure and technical expertise

FLORHAM

PARK, N.J. and SCOTTSDALE, A.Z., October 29, 2026—Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused

regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and

longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind,

U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (“APIs”).

The

collaboration expands Celularity’s regenerative longevity platform by applying Celularity’s U.S.-based manufacturing infrastructure

and technical capabilities to support the development of Vesalius’s Peptual®-branded peptide APIs at its Florham Park,

New Jersey facility. It builds on Celularity’s experience manufacturing complex biologics to current good manufacturing practice

(“cGMP”) standards, extending those capabilities into peptide API manufacturing while supporting its broader vision of advancing

regenerative longevity.

Under

the collaboration, Celularity will perform downstream purification, processing, analytical testing and manufacturing activities using

supplier-provided bulk peptide material. The work is intended to establish peptide-specific manufacturing processes that satisfy cGMP

requirements, supported by defined product specifications, documented sourcing and lot-level traceability. The collaboration is intended

to position the parties to respond to potential regulatory developments affecting peptide compounding. If and when the U.S. Food and

Drug Administration (“FDA”), following its consideration of recommendations from the Pharmacy Compounding Advisory Committee

(“PCAC”), adds covered peptide substances and forms to its list of bulk drug substances that may be used in compounding under

federal law, the parties intend to supply eligible Peptual-branded APIs to appropriately licensed U.S. compounding pharmacies. The collaboration

will not involve manufacturing GLP-1 receptor agonists or other weight-loss peptides, as these products are excluded from Vesalius’s

business model.

“Peptides

represent an important category of products which can work to augment the clinical utility of conventional therapeutics, and we believe

can complement our regenerative cellular products,” said Robert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer

of Celularity. “We have invested in a purpose-built U.S. facility and assembled a team with experience manufacturing complex medicines.

As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our

regenerative longevity strategy.”

The

collaboration comes amid regulatory scrutiny of the quality and provenance of imported pharmaceutical ingredients. The FDA has highlighted

concerns about peptide APIs from unverified foreign sources and has separately urged compounding pharmacies to verify their ingredient

suppliers, understand the testing performed and identify the original API manufacturer. Celularity and Vesalius believe these concerns

create an imperative for a domestic manufacturing platform to strengthen pharmaceutical supply-chain resilience and U.S. national health

preparedness. By bringing key downstream manufacturing activities onshore, the collaboration is intended to establish a more transparent

path from bulk peptide material through final API release.

“We

selected Celularity because its facility, technical personnel and experience manufacturing complex biological products provide a strong

foundation for our peptide API sourcing plans,” said Pradeep Albert, CEO of Vesalius. “Celularity’s capabilities complement

our Peptual platform and commercialization strategy. Together, we aim to establish a U.S. domestic supply platform supported by documented

manufacturing processes, defined quality specifications and traceability from supplier inputs through final API release.”

For

patients and prescribing physicians, uncertainty about an ingredient’s origin, identity and purity raises practical questions about

what is being supplied and the evidence supporting its quality. Meaningful transparency requires documentation connecting each lot to

its original source, the manufacturing controls applied and the testing supporting its release. The parties intend to build that accountability

into the planned platform, supporting informed sourcing decisions by pharmacies and providing a clearer basis for peptide use from prescribing

physicians and their patients.

“The

healthcare community deserves transparency about where the ingredients in medications originate and how their quality has been

evaluated,” said Micheal Roizen, M.D., former head of Wellness at Cleveland

Clinic and Chief Scientific Advisor at Vesalius. “When the original manufacturer is unclear or testing records are

incomplete, physicians and patients are left with questions that should be answered before a product is used. Vesalius’s

collaboration with Celularity is intended to bring greater visibility and accountability to that supply chain. That is an important

foundation for responsible progress in peptide medicine.”

Regulatory

Notice

The

peptides and APIs described in this release are not FDA-approved drug products. Compounded drugs are not FDA-approved and are not reviewed

by FDA for safety, effectiveness or manufacturing quality before marketing. FDA establishment registration, facility inspection, advisory

committee consideration or recommendations, cGMP terminology, a certificate of analysis or domestic manufacture does not constitute FDA

approval or endorsement of a substance, API, compounded drug, manufacturer or pharmacy. Execution of the collaboration agreement and

completion of development or qualification activities do not themselves authorize commercial release, distribution or use of any peptide

API. Availability is subject to applicable law, FDA policy and local jurisdictional requirements.

About

Vesalius Longevity Labs

Vesalius

Longevity Labs is a longevity science and regenerative health platform focused on peptides, biologics, preventative healthcare and performance

optimization. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers, telehealth infrastructure,

product fulfillment and advanced longevity therapeutics across global markets. Vesalius’s expanding ecosystem includes peptide

therapeutics, regenerative medicine initiatives, royalty-generating biologics partnerships and advanced provider enablement technologies

designed to support the future of personalized health and wellness.

For

more information, visit: https://www.vesaliuslabs.com/

Vesalius

Media Contacts:

Media

Contact: vesalius@jacktaylorpr.com

About

Celularity

Celularity

Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous

cell therapies and biomaterials. Celularity’s regenerative longevity vision centers on advancing technologies intended to address

aging and age-related conditions and extend healthspan. Its purpose-built facility in Florham Park, New Jersey supports manufacturing,

research and biobanking activities. Celularity also pursues contract development and manufacturing opportunities that apply its infrastructure

and technical expertise to third-party programs.

For

more information, visit www.celularity.com.

Celularity

Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding

the establishment, development and potential growth of Celularity’s peptide API manufacturing business vertical; its alignment

with Celularity’s regenerative longevity strategy; the anticipated scope, implementation and benefits of the collaboration with

Vesalius; the development and qualification of manufacturing processes that satisfy applicable cGMP requirements; potential commercial

supply and revenue generation; utilization of Celularity’s existing infrastructure; and anticipated benefits relating to quality,

traceability and domestic supply-chain resilience. These statements may be identified by words such as “anticipate,” “believe,”

“expect,” “intend,” “may,” “plan,” “potential,” “will” and similar

expressions, although not all forward-looking statements contain these words.

These

forward-looking statements reflect Celularity’s current expectations and assumptions and are subject to substantial risks and uncertainties

that could cause actual results to differ materially. These risks include the parties’ ability to agree upon and fund product-specific

development plans and commercial supply terms; complete technical transfer, process development, analytical-method qualification and

manufacturing qualification; establish peptide-specific processes and quality systems that satisfy applicable cGMP requirements; achieve

required specifications and commercial scale; and obtain and maintain required regulatory authorizations, registrations and licenses.

Additional risks include uncertain customer demand, the costs of establishing the new business vertical, Celularity’s ability to

generate revenue or achieve profitable operations, and changes in laws, regulations, FDA policies or enforcement priorities affecting

peptide manufacture, distribution or compounding. Particular peptide substances or forms may not be eligible for supply or use in the

intended channels. Celularity’s existing facility and manufacturing experience do not assure successful development or commercial

manufacture of any peptide API. Commercial supply may be delayed indefinitely or may not occur.

These

risks and uncertainties should be considered together with the risks described under “Risk Factors” and elsewhere in Celularity’s

most recent Annual Report on Form 10-K, as amended, subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities

and Exchange Commission. The risks described are not exhaustive. Forward-looking statements speak only as of the date of this release,

and readers should not place undue reliance on them. Except as required by law, Celularity undertakes no obligation to update any forward-looking

statement to reflect subsequent events, circumstances or changes in expectations.

Celularity

Investor and Media Contact

info@celularity.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 29, 2026

Entity File Number

001-38914

Entity Registrant Name

Celularity

Inc.

Entity Central Index Key

0001752828

Entity Tax Identification Number

83-1702591

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

170

Park Ave

Entity Address, City or Town

Florham

Park

Entity Address, State or Province

NJ

Entity Address, Postal Zip Code

07932

City Area Code

(908)

Local Phone Number

768-2170

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class

A Common Stock, $0.0001 par value per share

Trading Symbol

CELU

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration